Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection: a randomized trial
Jun Liu,Dan-Dan Li,Wei Dong,Yu-Qi Liu,Yang Wu,Da-Xuan Tang,Fu-Chun Zhang,Meng Qiu,Qi Hua,Jing-Yu He,Jun Li,Bai Du,Ting-Hai Du,Lin-Lin Niu,Xue-Jun Jiang,Bo Cui,Jiang-Bin Chen,Yang-Gan Wang,Hai-Rong Wang,Qin Yu,Jing He,Yi-Lin Mao,Xiao-Fang Bin,Yue Deng,Yu-Dan Tian,Qing-Hua Han,Da-Jin Liu,Li-Qin Duan,Ming-Jun Zhao,Cui-Ying Zhang,Hai-Ying Dai,Ze-Hua Li,Ying Xiao,You-Zhi Hu,Xiao-Yu Huang,Kun Xing,Xin Jiang,Chao-Feng Liu,Jing An,Feng-Chun Li,Tao Tao,Jin-Fa Jiang,Ying Yang,Yao-Rong Dong,Lei Zhang,Guang Fu,Ying Li,Shu-Wei Huang,Li-Ping Dou,Lan-Jun Sun,Ying-Qiang Zhao,Jie Li,Yun Xia,Jun Liu,Fan Liu,Wen-Jin He,Ying Li,Jian-Cong Tan,Yang Lin,Ya-Bin Zhou,Jian-Fei Yang,Guo-Qing Ma,Hui-Jun Chen,He-Ping Liu,Zong-Wu Liu,Jian-Xiong Liu,Xiao-Jia Luo,Xiao-Hong Bin,Ya-Nan Yu,Hai-Xia Dang,Bing Li,Fei Teng,Wang-Min Qiao,Xiao-Long Zhu,Bing-Wei Chen,Qi-Guang Chen,Chun-Ti Shen,Yong-Yan Wang,Yun-Dai Chen,Zhong Wang
DOI: https://doi.org/10.1038/s41392-021-00741-x
IF: 39.3
2021-09-01
Signal Transduction and Targeted Therapy
Abstract:Abstract It’s a challenge for detecting the therapeutic targets of a polypharmacological drug from variations in the responsed networks in the differentiated populations with complex diseases, as stable coronary heart disease. Here, in an adaptive, 31-center, randomized, double-blind trial involving 920 patients with moderate symptomatic stable angina treated by 14-day Danhong injection(DHI), a kind of polypharmacological drug with high quality control, or placebo (0.9% saline), with 76-day following-up, we firstly confirmed that DHI could increase the proportion of patients with clinically significant changes on angina-frequency assessed by Seattle Angina Questionnaire (ΔSAQ-AF ≥ 20) (12.78% at Day 30, 95% confidence interval [CI] 5.86–19.71%, P = 0.0003, 13.82% at Day 60, 95% CI 6.82–20.82%, P = 0.0001 and 8.95% at Day 90, 95% CI 2.06–15.85%, P = 0.01). We also found that there were no significant differences in new-onset major vascular events ( P = 0.8502) and serious adverse events ( P = 0.9105) between DHI and placebo. After performing the RNA sequencing in 62 selected patients, we developed a systemic modular approach to identify differentially expressed modules (DEMs) of DHI with the Z summary value less than 0 compared with the control group, calculated by weighted gene co-expression network analysis (WGCNA), and sketched out the basic framework on a modular map with 25 functional modules targeted by DHI. Furthermore, the effective therapeutic module (ETM), defined as the highest correlation value with the phenotype alteration (ΔSAQ-AF, the change in SAQ-AF at Day 30 from baseline) calculated by WGCNA, was identified in the population with the best effect (ΔSAQ-AF ≥ 40), which is related to anticoagulation and regulation of cholesterol metabolism. We assessed the modular flexibility of this ETM using the global topological D value based on Euclidean distance, which is correlated with phenotype alteration ( r 2 : 0.8204, P = 0.019) by linear regression. Our study identified the anti-angina therapeutic module in the effective population treated by the multi-target drug. Modular methods facilitate the discovery of network pharmacological mechanisms and the advancement of precision medicine. (ClinicalTrials.gov identifier: NCT01681316).
biochemistry & molecular biology,cell biology